BioLife Solutions Inc. Invests $2 Million in Pluristyx, Expanding Strategic Partnership in Cell Therapy Innovation

Reuters

07/28

<a href="https://laohu8.com/S/BLFS">BioLife Solutions Inc.</a> Invests $2 Million in Pluristyx, Expanding Strategic Partnership in Cell Therapy Innovation

BioLife Solutions Inc., a prominent developer and supplier of bioproduction products and services for the cell and gene therapy market, has made a strategic investment in Pluristyx, Inc., a Seattle-based company specializing in induced pluripotent stem cell-based products for cell therapy developers. The investment involves the purchase of $2 million in convertible notes as part of a larger financing round. Additionally, BioLife Solutions has secured a board observer seat and certain rights concerning potential future acquisitions of Pluristyx. This investment aligns with BioLife's strategy of expanding its portfolio, as noted by Roderick de Greef, BioLife's Chairman and CEO. Pluristyx's CEO, Benjamin Fryer, expressed appreciation for BioLife's support, which will aid in the commercialization of Pluristyx's innovative solutions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLife Solutions Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA38210) on July 28, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2554779426"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2554779426\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2554779426?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-28 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2554779426","market":"us","top_or_hot":-1,"title":"BioLife Solutions Inc. Invests $2 Million in Pluristyx, Expanding Strategic Partnership in Cell Therapy Innovation","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BLFS\">BioLife Solutions Inc.</a> Invests $2 Million in Pluristyx, Expanding Strategic Partnership in Cell Therapy Innovation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioLife Solutions Inc., a prominent developer and supplier of bioproduction products and services for the cell and gene therapy market, has made a strategic investment in Pluristyx, Inc., a Seattle-based company specializing in induced pluripotent stem cell-based products for cell therapy developers. The investment involves the purchase of $2 million in convertible notes as part of a larger financing round. Additionally, BioLife Solutions has secured a board observer seat and certain rights concerning potential future acquisitions of Pluristyx. This investment aligns with BioLife's strategy of expanding its portfolio, as noted by Roderick de Greef, BioLife's Chairman and CEO. Pluristyx's CEO, Benjamin Fryer, expressed appreciation for BioLife's support, which will aid in the commercialization of Pluristyx's innovative solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLife Solutions Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA38210) on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioLife Solutions Inc. Invests $2 Million in Pluristyx, Expanding Strategic Partnership in Cell Therapy Innovation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioLife Solutions Inc. Invests $2 Million in Pluristyx, Expanding Strategic Partnership in Cell Therapy Innovation\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-28 20:05</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/BLFS\">BioLife Solutions Inc.</a> Invests $2 Million in Pluristyx, Expanding Strategic Partnership in Cell Therapy Innovation\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        BioLife Solutions Inc., a prominent developer and supplier of bioproduction products and services for the cell and gene therapy market, has made a strategic investment in Pluristyx, Inc., a Seattle-based company specializing in induced pluripotent stem cell-based products for cell therapy developers. The investment involves the purchase of $2 million in convertible notes as part of a larger financing round. Additionally, BioLife Solutions has secured a board observer seat and certain rights concerning potential future acquisitions of Pluristyx. This investment aligns with BioLife's strategy of expanding its portfolio, as noted by Roderick de Greef, BioLife's Chairman and CEO. Pluristyx's CEO, Benjamin Fryer, expressed appreciation for BioLife's support, which will aid in the commercialization of Pluristyx's innovative solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLife Solutions Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA38210) on July 28, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科學工具和服務","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nNDL3NN6Bj:1","article_id":"2554779426","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2554779426","pubTimestamp":1753704323,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BioLife Solutions Inc., a prominent developer and supplier of bioproduction products and services for the cell and gene therapy market, has made a strategic investment in Pluristyx, Inc., a Seattle-based company specializing in induced pluripotent stem cell-based products for cell therapy developers. The investment involves the purchase of $2 million in convertible notes as part of a larger financing round. Additionally, BioLife Solutions has secured a board observer seat and certain rights concerning potential future acquisitions of Pluristyx. This investment aligns with BioLife's strategy of expanding its portfolio, as noted by Roderick de Greef, BioLife's Chairman and CEO. Pluristyx's CEO, Benjamin Fryer, expressed appreciation for BioLife's support, which will aid in the commercialization of Pluristyx's innovative solutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely info","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","BLFS":"BioLife Solutions Inc.","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK4198":"医疗保健用品","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC"},"translate_title":"BioLife Solutions Inc.向Pluristyx投资200万美元，扩大细胞治疗创新战略合作伙伴关系","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BLFS":0.9},"content_text":"BioLife Solutions Inc. Invests $2 Million in Pluristyx, Expanding Strategic Partnership in Cell Therapy Innovation\n    \n\n        BioLife Solutions Inc., a prominent developer and supplier of bioproduction products and services for the cell and gene therapy market, has made a strategic investment in Pluristyx, Inc., a Seattle-based company specializing in induced pluripotent stem cell-based products for cell therapy developers. The investment involves the purchase of $2 million in convertible notes as part of a larger financing round. Additionally, BioLife Solutions has secured a board observer seat and certain rights concerning potential future acquisitions of Pluristyx. This investment aligns with BioLife's strategy of expanding its portfolio, as noted by Roderick de Greef, BioLife's Chairman and CEO. Pluristyx's CEO, Benjamin Fryer, expressed appreciation for BioLife's support, which will aid in the commercialization of Pluristyx's innovative solutions.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioLife Solutions Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA38210) on July 28, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}